Liminatus Pharma Stock Soars 18.58% on Rebranding

On July 10, 2025, Liminatus Pharma's stock surged by 18.58% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Liminatus Pharma, formerly known as IRIS ACQUISITION CORP, recently underwent a ticker change to LIMN and a corporate name change to Liminatus Pharma, Inc. This rebranding effort is part of the company's strategic move to better align with its pharmaceutical focus and future growth plans.

Despite the recent surge, Liminatus Pharma has faced challenges in the past month, experiencing a significant decline in its stock price. This volatility reflects the broader market's uncertainty and the company's ongoing efforts to stabilize its financial performance.

Investors are closely monitoring Liminatus Pharma's developments, particularly its cash flow statements and strategic initiatives. The company's ability to navigate these challenges and capitalize on its rebranding efforts will be crucial in determining its future trajectory.